Status:
RECRUITING
ALG-LungCancerRegistry (SAFRO2202)
Lead Sponsor:
Société Algérienne de Formation et de Recherche en Oncologie
Collaborating Sponsors:
AstraZeneca
Conditions:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Brief Summary
SAFRO 2202 ALG-Lung Cancer Registry is a prospective, multicenter, non-interventional observational study conducted across 21 public and university hospitals in Algeria. The objective is to characteri...
Detailed Description
Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide, and its incidence continues to rise in Algeria. Despite this increasing burden, real-world data regarding the epid...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologically confirmed diagnosis of lung cancer (NSCLC, SCLC, or carcinoid tumor)
- Diagnosed at the time of inclusion or within the 12 previous months
- Fully managed (diagnosis, treatment, and follow-up) in an oncology or pulmonology department of one of the 21 participating public/university hospitals
- Signed informed consent obtained
Exclusion
- Prior enrollment in this study
- Participation in an interventional clinical trial
Key Trial Info
Start Date :
June 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
3750 Patients enrolled
Trial Details
Trial ID
NCT07161882
Start Date
June 1 2025
End Date
December 1 2027
Last Update
September 16 2025
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Pierre et Marie Curie
Algiers, Algiers Province, Algeria, 16000
2
Chu Beni Messous - Isaad Hassani
Algiers, Algiers Province, Algeria, 16000
3
CHU Mohamed Lamine Debaghine - Bab-el-Oued
Algiers, Algiers Province, Algeria, 16000
4
Chu-Beni Messous - Isaad Hassani
Algiers, Algiers Province, Algeria, 16000